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A B S T R A C T
The resonant coil magnetometer quantifies paramagnetic particles (PMPs) and has been used to develop mag-
neto-immunoassays in a range of formats. The advantage of magneto-immunoassays is that they are relatively
inexpensive, portable, easy to perform and give results in under 5 min. Porcine Reproductive and Respiratory
Virus (PRRSV) is an infection of domesticated pigs producing large economic losses in the swine industry current
diagnosis is performed using commercially available ELISA kits. Here we describe the development of a com-
petitive magneto-immunoassay (MIA) and pilot study with porcine serum samples. The data show that this
technology has the potential for use as a rapid and portable in field system for the detection of antibodies in
porcine serum to PRRSV. A range of assay parameters and magnetometer settings were optimised, including the
concentration of antibody conjugated PMPs used in the assay and movement of an external magnet to pull
particles to a sensor surface. PRRSV positive control serum demonstrated competition with antibody conjugated
PMPs with a dose dependent relationship. The magneto-immunoassay developed showed good agreement with
the PRRS IDEXX X3 ELISA. The PRRSV magneto-immunoassay demonstrated a sensitivity of 73% and specificity
of 100%. The results suggest that a rapid assay using the magnetometer technology detects specific anti-PRRSV
antibody in pig serum. The magneto-immunoassay is suitable for use as a rapid ‘on-site’ method for the ser-
ological detection of PRRSV infection.
1. Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV), is an
infection of domesticated pigs producing large economic losses in the
swine industry worldwide and is currently considered to be the most
economically important infectious disease that is faced by the swine
industry. PRRSV is a small enveloped, single-stranded positive-sense
RNA virus approximately 50–65 nm in diameter and belongs to the
family Arteriviridae. The genome of PRRSV is approximately 15 kb in
length and is comprised of at least ten open reading frames (Orfs) [1–3].
PRRSV consists of two species: PRRSV-1 isolates are of European origin
while PRRSV-2 originated in North America, the disease was first ob-
served in the 1980's [4,5] and is now prevalent throughout the US,
Europe and Asia. In the United States PRRSV infection results in losses
of over $664 million annually [6–8]. In Europe estimates of losses have
been made using a disease model and could be up to €650,090 per farm
[8]. PRRSV-1 and PRRSV-2 share ~60% identity at the nucleotide level,
in addition, each species can be further divided into several clades or
substrains [9]. The key consequence of PRRSV infection is a respiratory
disease in piglets characterized by fever, lethargy, and failure to thrive
frequently developing into interstitial pneumonia. Other effects of
PRRSV infection include abortion, weak piglets, and mummification
together with stillbirth. The effects of PRRSV infection result in ele-
vated mortality amongst piglets [10,11]. Infection of adult pig's parti-
cularly male boars however is largely asymptomatic, but flu-like
symptoms are observed in the finishing phase affecting weight.
Current control measures involve detecting infected individual pigs
and farms using commercially available ELISA kits e.g. IDEXX PRRSV
X3™ to detect the presence of antibodies to PRRSV, followed by vac-
cination. The IDEXX PRRSV X3™ ELISA is an indirect immunoassay
utilising peptide fragments of the highly immunogenic PRRSV nucleo-
protein (N), also known as open reading frame protein 7 (Orf7) as the
antigen. PRRSV Orf7 is highly immunogenic and induces early antibody
responses in pigs [12]. PRRS ELISA assays are the mainstay of pig
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testing programmes, however there are several limitations of ELISA
assays. ELISA assays are performed in laboratories by specialist staff,
the assays require several incubation and wash steps and take several
hours to complete. In the UK, porcine blood samples are collected by a
veterinary surgeon and transported to a laboratory for analysis by
ELISA. This can cause a delay between sample collection and reporting
of results and therefore a delay in the implementation of control mea-
sures. In the study described paramagnetic particles (PMPs) are used as
a label in immunoassays. The PMPs are quantified using a device the
Resonant Coil Magnetometer (RCM), [13], (Patent, WO 2008/114025).
The advantages of this technology are that the assay matrix has little
effect on the assay measurements, it is relatively inexpensive, gives
results within minutes and is easy to use and therefore has the potential
for development for use onsite by non-technical individuals.
The aim of this investigation is to show the development of a
magneto-immunoassay to detect antibodies to PRRSV in porcine serum
and the potential for use of this technology for rapid, cost effective “on-
site” diagnosis of PRRSV.
2. Materials and methods
2.1. Serum samples
IDEXX X3 tested frozen porcine serum samples (n = 22) taken
during normal veterinary surveillance were supplied by Clarity
BioSolutions and were kept at −20 °C until testing.
2.2. PRRSV Orf7
The Orf7 was kindly provided by Professor Vladimir Celer
(University of Veterinary and Pharmaceutical Sciences, Brno, CZ) which
was produced by expressing and purifying the PRRSV Orf7 sequence of
the Lelystad strain of PRRSV in E.Coli. The recombinant PRRSV Orf7
included an N-terminal x6 His Tag. Orf7 was prepared immediately
prior to use by centrifugation at 10,000 ×g to sediment any protein
aggregates, the protein concentration of the supernatant was de-
termined using the Bicinchoninic Acid assay (BCA assay), ThermoFisher
Scientific, (Loughborough, UK).
2.3. Magnetometer and assay cuvettes
Instead of an enzyme label and colorimetric read out as in ELISA,
PMPs are detected by virtue of their magnetic properties by a device,
the resonant coil magnetometer (RCM), Fig. 1. PMP numbers correlate
directly with the voltage output of the RCM [13]. Magneto-im-
munoassays have been developed in a range of immunoassays formats
[14–16]. This is the first study where a magneto-immunoassay has been
developed for serology. A diagrammatic representation of the PRRSV
Magneto-immunoassay is shown in Fig. 2.
The RCM was developed at the University of the West of England and
a prototype instrument produced by Clarity BioSolutions Ltd. in colla-
boration with Sarum Scientific Ltd. to take individual assay polystyrene
cuvettes (Fig. 1). The assay cuvettes manufactured by Boddingtons
Plastics Ltd., Tonbridge, UK were 15.9 mm diameter clear orientated
Polyflex polystyrene discs which had a 5 mm central hole. The base of
the well in the cuvette was formed by the attachment of 100 μm thick
polystyrene film (Sidaplex, La Giraud, France) using 3M9485 pressure
sensitive adhesive (3M PLC, 3M Centre, Bracknell, UK). This thin poly-
styrene base formed the sensor surface and was positioned directly above
the resonant coil of the magnetometer which had a 3 mm spiral coil.
When the assay cuvette was placed in the magnetometer the ex-
ternal magnet moves into position under the resonant coil for 1 min to
pull particles to the sensor surface. After this time the external magnet
retracts and non-bound particles diffuse away from the surface. An
individual result is taken as the difference in millivolts of the data trace
at points A and B as shown in Fig. 1.
2.4. Preparation of paramagnetic particles
Dynal Tosylated 1 μm paramagnetic particles (PMPs), Invitrogen,
Paisley, Scotland were coated with anti-PRRSV Orf7 nucleoprotein
Fig. 1. Magnetometer and polystyrene consumable in position.
a. Data trace showing an increase in voltage when the external magnet moves
in and out in relation to the magnetometer coil ie. the ''magnetic dwell''
time.
b. The magnetic dwell time of the external magnet and effect on the baseline
before and after approach if paramagnetic particles are absent (a) or present
(b).
Fig. 2. Diagram to show the principle of the competitive magneto-im-
munoassay for anti-PRRSV antibodies
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(SDOW17A -Rural Technologies Inc., South Dakota, USA), a mouse
monoclonal antibody, using 0.1 M borate buffer pH 9.5, at 37 °C for 1 h
as described in the manufacturer's conjugation protocol. Prior to con-
jugation the antibody was mixed with normal goat serum or bovine
serum albumin (BSA), (Sigma-Aldrich, Poole, UK) to give anti-PRRSV
antibody concentrations of 0%, 0.3%, 1.25% and 5% of the total
amount of protein. Forty migrogram protein/mg beads was conjugated
to the particles. Following addition of protein the PMPs were sonicated
for 4 × 30s pulses with 60s intervals at a setting of 10 μm using a
Soniprep 150 sonicator (MSE, Lower Sydenham, UK) and again at 3.5 h
post conjugation to ensure the dispersal of any PMP aggregates formed
during conjugation. PMPs were stored at 4 °C in 500 μl of storage buffer
(0.1% bovine serum albumin (BSA, Probumin, EMD Millipore UK
Limited, Dundee, Scotland) and 0.05% Tween 20 (Sigma-Aldrich,
Poole, UK) in phosphate buffered saline (PBS) until needed. The coated
PMPs were used for up to 4 weeks post conjugation.
Confirmation of antibody conjugation to the PMP was carried by
determining the quantity of anti-PRRSV Orf7 immobilized on the PMPs
using a secondary antibody with a horse radish peroxidase (HRP) label.
Briefly, 5 μl of PMPs (adjusted to 1 × 1010 PMP/ml) was added to
500 μl of a 1:2000 dilution of rabbit anti-mouse/HRP antibody (Dako,
Cambridge, UK) in dilution buffer (1% BSA, 0.05% Tween 20 in PBS).
The tube was incubated for 1 h at 37 °C on a Dynal rotator. Following
incubation the PMPs were washed three times with 500 μl of wash
buffer (0.1% BSA, 0.05% Tween 20 in PBS). The PMPs were vortexed
well after each wash to re-suspend the PMPs. After the final wash the
PMPs were transferred to a fresh tube and re-suspended in 100 μl of
wash buffer. Three 10 μl aliquots of suspended PMPs were transferred
into fresh tubes to which 100 μl of the HRP substrate, Tetra Methyl
Benzidine (TMB), ThermoFisher Scientific, Loughborough, UK) was
added. The PMPs were mixed and incubated at room temperature for
4 min before 100 μl of 1 M H2SO4 stop solution was added. The PMPs
were removed from the supernatant with the aid of a DynaMag™
magnet (ThermoFisher Scientific, Paisley, UK). The supernatant was
transferred into a well of a 96 well micro-titre plate and the absorbance
measured at 450 nm on a microplate reader (Anthos II, Anthos Labtec
Instruments GmbH, Austria).
The effect of the antibody loading in a magnetic assay was in-
vestigated using assay cuvettes coated with PRRSV Orf7 at a con-
centration of 5 μg/ml, as described below. One hundred microlitre of
PMPs prepared as described containing 5 × 107 antibody conjugated
PMPs was added to each assay cuvette and inserted into the magnet-
ometer to record the assay trace.
2.5. Sensor surface preparation
The polystyrene sensor surface was first activated using proprietary
binding reagent (PBR), (Mix&Go, Anteo Diagnostics, Brisbane,
Australia). The recombinant PRRSV Orf7 which contains a x6 His Tag at
the N-terminal was immobilized on the sensor surface via a mouse anti-
HIS antibody (Life Technologies, Paisley, Scotland).
To activate the polystyrene surface, 40 μl of a proprietary binding
reagent was added to an assay cuvette and incubated for 1 h at room
temperature. The PBR was removed and the assay cuvettes washed
twice with 250 μl of PBS and once with 250 μl of deionised water. Then
50 μl of mouse anti-His antibody (1/100 or 1/500 in PBS) was added to
the cuvette and incubated for 1 h at 37 °C after which each assay
cuvette was washed three times with 250 μl of wash buffer (0.05%
Tween 20 in PBS). Finally the sensor surface was blocked by adding
200 μl of 2.5% BSA in PBS and incubating overnight at 4 °C.
After incubation each cuvette was washed three times with 250 μl of
PBS/0.05% Tween 20 and 50 μl of PRRSV Orf7 solution diluted in PBS
(concentrations of: 0, 10, 20 and 40 μg/ml) was added. After incubation
at 37 °C for 1 h in a humidified atmosphere each consumable was
washed three times with 250 μl of PBS + 0.05% Tween 20 to remove
unbound PRRSV Orf7 and then stored in 200 μl of PBS/1%BSA/0.02%
sodium azide until use.
To demonstrate PRRSV on the sensor surface, 100 μl mouse
monoclonal anti – PRRSV-Orf7, diluted to 500 ng/ml in dilution buffer
was added to cuvettes and incubated at 37 °C for 1 h. Antibody was
removed and all wells were washed four times in wash buffer, then
50 μl of rabbit anti mouse Ig-HRP conjugate (Dako Limited, Ely, UK)
diluted 1/1000 in dilution buffer was added to each cuvette and in-
cubated for 1 h at room temperature. The antibody was removed and
the cuvette washed four times in wash buffer followed by the addition
of 50 μl of TMB substrate (Sigma-Aldrich, Poole, UK). After a 5 min
incubation at room temperature 50 μl of 1 M H2SO4 stop solution was
added and the plate read at an absorbance of 450 nm on a microplate
reader.
The effect of PRRSV Orf7 loading on the sensor surface in a mag-
neto-immunoassay was investigated using assay cuvettes coated with
PRRSV Orf7 at concentrations of: 0, 10, 20 and 40 μg/ml as described
above. Ten microlitre of PMPs (containing 5 × 107 PMPs with a 1.25%
antibody loading) was added to each assay cuvette and inserted into the
magnetometer to record the assay trace.
2.6. Validation of sensor surface by ELISA (Confirmation that antibody
conjugated PMPs bind to the PRRSV ORF7 coated consumable surface)
PRRSV Orf7 coated consumables were prepared and blocked as
described above. Porcine PRRSV antibody positive serum (LSI-EU) or
PRRSV antibody negative serum, (MRI negative) both from LSIVet™,
Life Technologies Corporation, Lissieu, France, was added to each
consumable. Sera were diluted in assay buffer (1/200, 1/400, 1/600, 1/
800) and 100 μl of diluted sera or assay buffer added. The consumables
were incubated for 1, 15, 30 and 60 min and then the sera were re-
moved by washing such that only Orf7 bound antibodies were detect-
able by enzyme immunoassay as described in Section 2.5 above.
2.7. PRRSV Magneto-immunoassay
Anti-PRRSV antibody coated PMPs (1.25% anti-PRRSV antibody in
goat serum) were diluted in assay buffer (1% BSA, 0.2% PEG6000
(Sigma-Aldrich, Poole, UK) in PBS) to achieve a concentration of
5 × 108 PMPs/ml and sonicated 3 × 20 s pulses with the sonicator set
to an amplitude of 10 μm.
Experiments with PRRSV antibody positive (Porcine PRRS/EU-
Serum, LSI-EU) and a PRRSV antibody negative, (MRI negative) control
sera both from LSIVet™, (Life Technologies Corporation, Lissieu,
France) were performed to demonstrate the magneto-immunoassay.
Four concentrations of PMPs were tested containing 0.5 × 107,
1.0 × 107 and 2.0 × 107 antibody conjugated PMPs. Here, 50 μl of
assay buffer or 50 μl of serum was added to an eppendorf tube con-
taining 100 μl of PMPs containing the PMP numbers described, the
cuvette was washed 4× with assay buffer. Then 150 μl of PMP/serum
or PMP/assay buffer was added to each assay cuvette and placed in the
magnetometer to obtain the data trace. For magneto-immunoassays
with test sera, PMPs were diluted prior to use such that a 150 μl volume
contained 0.5 × 107 PMPs. One hundred and fifty microlitre of PMPs
was mixed with 50 μl of test serum or assay buffer for the blank, and
added to the assay cuvette, coated with 5 μg/ml Orf7 as described
above. The consumable was then placed immediately into the mag-
netometer and the measurement cycle started. Results were expressed
as a ratio of the test sample (S) sera voltage change (defined above) and
the no serum, termed blank (B) thereafter voltage change.
2.8. Sample testing
A pilot study in the PRRSV magneto-immunoassay was performed
on 22 serum samples from pigs that were identified as being positive or
negative for PRRSV antibodies using the commercial IDEXX PRRS X3
ELISA kit (IDEXX Laboratories, NL). The ELISA tests were performed
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according to the manufactures instructions and results read using an
Anthos II plate reader (Anthos Labtec Instruments GmbH, Austria) at
550 nm. The results were calculated according to the manufactures
instructions where a positive result was defined when the ratio of the
sample absorbance/positive control absorbance (after subtraction of the
background control from each) was> 0.4. For the Magneto-im-
munoassay the mean voltage change from triplicate samples was de-
termined and the sample voltage change/positive control voltage
change determined. A positive result was determined using the S/B
result for 1/400 and 1/2000 dilutions of the LSI positive control in the
magneto-immunoassay, i.e. average S/B ratio of the two results. The
dilutions of the LSI positive control chosen are always positive and
negative respectively in the IDEXX PRRS X3 assay (n = 3).
3. Data analysis
All assays were performed in triplicate and the Mean and Standard
error of the mean (SEM) were determined. The S/P ratio of each sample
in the PRRS IDEXX X3 ELISA and the S/B ratio of each sample in the
PRRSV Magneto-immunoassay were calculated using mean values.
Positive and negative PRRSV samples were determined in the PRRS
IDEXX X3 ELISA according to the manufacturer's instructions where any
sample with an S/P ratio is> 0.4 is positive. In the PRRSV Magneto-
immunoassays a cut-off value was determined using the mean of the
MIA results for the LSI-EU control tested at 1/800 and 1/2000 dilutions,
which are positive and negative in the PRRS IDEXX X3 ELISA respec-
tively.
The Sensitivity, Specificity, Positive Predictive Value (PPV) and
Negative Predictive Value (NPV) for the Magneto-immunoassay were
determined by comparing the number of positive and negative samples
detected in relation to the PRRS IDEXX X3 assay.
4. Results
4.1. Assay development
4.1.1. Use of Mix&Go to activate the consumable surface
The base of each consumable is comprised of 100 μm thick poly-
styrene film. The polystyrene in ELISA plates is ɣ- irradiated and results
in the formation of a charged surface, such that charged molecules e.g.
proteins will attach to the surface through many hydrogen bonds.
Polystyrene film is uncharged and therefore to use this substrate in an
immunoassay the surface needs to be functionalised or charged. In this
study we achieved this by activating the surface with Mix&Go a com-
mercially available Activation Reagent where metal polymers allow
binding to negatively charged residues on proteins https://www.
anteotech.com/. The success of this pre-treatment to increase PRRSV
Orf7 binding to the polystyrene substrate can be seen in Fig. 3. The use
of Mix&Go gave up to a 3-fold enhancement of the activity of the sensor
compared with preparation of the surface with PBS. This demonstrates
the effectiveness of polymeric metal ions in the product to attach pro-
teins to synthetic surfaces.
4.1.2. Improved interaction of PRRSV Orf7 and anti-PRRSV antibody
through pre-adsorption of anti-HIS antibody
PRRSV Orf7 is a recombinant antigen that has an N-terminal x6 HIS
tag, this feature was used to ensure that PRRSV Orf7 was specifically
bound to the polystyrene substrate by the prior addition of anti-HIS
antibody. The antigen bound will also all be orientated in the same way
which could improve interaction with anti-PRRSV Orf7 antibody. This
was tested by comparing the amount of PRRSV-Orf7 detected plus and
minus anti-HIS antibody. The data in Fig. 4 shows the comparison of
two concentrations of anti-HIS antibody 1:100 and 1:500 with a range
of concentrations of PRRSV Orf7 5-40 μg/ml. At the 1:100 dilution of
anti-HIS antibody an increase in the amount of antigen detected was
observed across all antigen concentrations. This occurred either
through increased amount of PRRSV Orf7 binding or improved or-
ientation of the antigen to improve interaction with antibody. This
concentration was used in all future experiments.
4.1.3. Evaluation of the optimum antibody concentration and blocking
agents used to conjugate PMPs
The amount of antibody present on the PMPs is an important factor
in developing an immunoassay, as this determines the total number of
antibody binding sites that will be available in the competitive assay.
Experiments were performed to demonstrate the effect of anti-PRRSV
antibody loading on the PMPs and the loading of PRRSV Orf7 on the
sensor surface. The immune-enzymatic assay reflected the total amount
of antibody immobilized to the particles, which increases as the anti-
body loading increased as expected as seen in Fig. 5. However the
variability in the amount of antibody loaded also increases with the
antibody loading concentration, this could potentially lead to unwanted
variability in magneto-immunoassay results. In addition the error bars
of the 1.5% and 5% preparations overlapped indicating that the total
amount of antibody possible was saturating. For this reason PMPs were
conjugated at a concentration of 1.5% in future experiments.
Magnetometer measurements in magneto-immunoassays are de-
tecting the number of PMPs binding to the antigen coated consumable
surface. In an experiment with increasing antibody loading 0.3–5% of
total protein, the number of particles used per cuvette was 5 × 107
Fig. 3. Graph to show the effect of Mix & Go on the binding of PRRSV Orf7
antigen to the consumable surface.
Fig. 4. Effect of anti-HIS antibody concentration on the interaction of anti-
PRRSV antibody conjugated PMPs with PRRSV Orf7 coated consumables.
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particles, the results are shown in Fig. 6. An antibody loading of 1.25%
antibody gave the highest signal which corresponded to the best signal
to noise ratio of the ELISA experiment. There are a greater number of
antibody molecules on the surface of the particles with 5% antibody
loading and it would be expected that this would generated the highest
number of particles binding to the surface. However in these experi-
ments the highest antibody loading of 5% did not correspond to the
highest signal generated. The higher antibody concentration may have
produced a reduced signal, due to steric hindrance or other mechanism
resulting in a loss of antibody availability on the particles for binding to
the antigen.
A number of blocking agents were investigated for use in PMP
conjugation (data not shown). The best two were normal goat serum
and bovine serum albumin see Fig. 7. The use of normal goat serum to
dilute antibody for coating paramagnetic particles resulted in higher
amounts of antibody binding to the particles compared to when bovine
serum albumin was used to dilute the antibody across a range of anti-
body concentrations. This difference was particularly noticeable at a
5% antibody concentration, where the use of goat serum resulted in
over twice as much antibody being immobilized on the particles.
Normal goat serum was therefore used to prepare all PMP preparations
in future experiments.
4.1.4. Evaluation of time of contact of PRRSV Orf7 antigen and PRRSV
positive and negative porcine antibodies by ELISA
An experiment was performed to investigate the binding of PRRSV
antibody positive and negative control sera (LSI-EU PRRSV positive and
MRI PRRSV negative) to PRRSV Orf7 antigen. Bound antibodies were
detected by anti- porcine- HRP tagged antibody.
As might be expected, the results in Fig. 8. show that increasing the
incubation time of serum with PRRSV Orf7 coated sensor surfaces from
1 to 60 min, increased the amount of antibody binding to the surface. It
would be expected that PRRSV Orf7 negative sera would not bind to
PRRSV Orf7 antigen. Indeed results of the negative sample gave lower
readings than the no antigen control after a 1 min incubation. At 15 min
the negative sample at 1/200 and 1/400 dilutions gave results equal to
the no antigen control. However as the length of time of incubation
increased up to 60 min, the signal from the negative sample increased
steadily to give readings greater than the no antigen control. These
results suggests that low affinity, non-specific antibodies present in the
serum are binding to the sensor surface which would result in high
background readings. At 1 min incubation it is primarily high affinity
antibody binding to the sensor surface and indicates that immunoassays
Fig. 5. Binding of PMPs plus or minus antibody conjugation to PRRSV Orf7
coated consumable surface ELISA.
Fig. 6. Effect of anti-PRRSV antibody concentration used during conjugation on
voltage difference in the PRRSV magneto-immunoassay
Fig. 7. Optimisation of blocking agent for preparation of PMP antibody con-
jugate
Fig. 8. Graph to show binding of anti-PRRSV Orf7 antibody to a PRRSV Orf7
coated consumable surface by ELISA incubated with a range of dilutions of
PRRSV antibody positive and negative sera, at four time points.
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performed and read with short incubation times approximately 1 min
should have a lower background values.
It has been shown previously that pulling particles onto a sensor
surface by the magnetometer dramatically reduces assay times [17].
These results suggest that a short magnetometer cycle would capture
high affinity antibodies in the sample and less non-specific ones. Eva-
luation of the PRRSV magneto-immunoassay with a magnetic dwell
time of 1–5 min showed that the optimum period for the external
magnet to be in position below the sensing coli was 1 min. These results
are consistent with the data presented above and therefore a magnetic
dwell time of 1 min was in future experiments.
4.1.5. Evaluation of particle number for use in the PRRSV MIA
The importance of particle number in a magneto-immunoassay was
demonstrated using commercially available PRRSV positive and nega-
tive serum samples. In a competitive magneto-immunoassay PRRSV
positive samples contain antibodies to PRRSV that bind to the antigen
on the sensor surface, thus preventing anti-PRRSV antibody conjugated
particles from binding to the surface.
Experiments were performed to evaluate the PMP concentration to
use in the Competitive magneto - immunoassay. In these experiments
anti-PRRSV antibody coated particles at three dilutions were mixed
with a 1/50 dilution of the serum sample and added to the assay cuv-
ette. On commencement of the magnetometer cycle, particles are ra-
pidly pulled to the surface and binding takes place between the anti-
body and the surface antigen and immobilises the particle to the surface
which reduces the resonant frequency of the coil, while unbound par-
ticles diffuse from the surface when the magnetic field is removed and
have little effect on the coil. An example of the results obtained is
shown in Fig. 9, the signal from the cuvettes with no PRRSV Orf7 on the
surface is due solely to paramagnetic particles present in solution above
the sensor and within the magnetic field, with voltage difference in-
creasing as the number of particles increases.
It can also be seen in Fig. 9 that when using 0.5 × 107 particles, the
signal is greater for both the positive serum and negative serum, in-
dicating that binding is taking place on the sensor surface. Here there is
a lower response in the test with a positive serum sample compared to
the result of a negative sample, as would be expected due to the com-
petitive nature of the assay. When higher numbers of particles are used
in the assay this differential between the positive and negative samples
is lost. When 2 × 107 particles were used there was little difference
between the positive serum, the negative serum and the blank as the
mass of magnetic material is saturating the resonant coil and there is a
large excess of paramagnetic particles which prevent diffusion of the
unbound particles from the surface. This large mass of unbound
particles is also detected by the coil masking the signal from specific
interactions on the sensor surface. A similar result is observed when
1 × 107 particles are used in the assay but the magnitude of the
measurements are reduced. This demonstrates the critical effect that the
particle number has on the assay design. Ideally, when there is a
number of particles that cover the surface with a monolayer all the
particles will be captured. Adding a competitive antibody as found in a
positive serum sample will reduce the number of particles that can bind
to the surface. In this study 0.5 × 107 particles were used in all assays
on serum samples.
4.2. PRRSV Magneto-immunoassay results
4.2.1. Evaluation of PRRSV positive and negative control sera in the PRRSV
magneto-immunoassay and determination of the assay cut-off value
The magneto-immunoassay measured the difference in the base line of
the magnetometer trace before and after the first magnetic “pull-down” of
particles on to the sensor surface. In the case of a PRRSV positive sample
there are antibodies in the sample that compete with the antibody on the
particle surface for the antigen immobilized on the sensor surface re-
sulting in fewer particles binding to the surface and results in a lower
response by the magnetometer. The mean voltage change results from the
magneto-immunoassay are calculated from the ratio of the sample result/
blank result. The blank was the assay in which there was no serum sample
added and the maximum number of particles bind to the sensor surface.
In this study the cut-off value for a positive sample was determined from
the MIA mean S/B ratio of the PRRSV LSI-EU positive control S/B ratio at
1/800 and 1/2000 dilutions i.e. PRRS IDEXX X3 positive and negative
dilutions of the positive control, the S/B cut-off using these values was
determined to be of 1.06 see Table 1 below.
4.2.2. Evaluation of PRRSV positive and negative porcine serum samples (n
= 22) by PRRSV magneto-immunoassay and PRRS X3 IDEXX ELISA
To demonstrate the utility of the magneto-immunoassay a pilot
study to test 22 PRRS IDEXX X3 confirmed positive and negative serum
samples in the magneto-immunoassay in triplicate was performed. The
ELISA test defines the test result as being the ratio of the sample ab-
sorbance and the absorbance of the positive control supplied in the
assay kit. A test result> 0.4 was defined as being positive. This test is
the mainstay of pig testing programmes.
The PRRSV MIA PRRSV positive and negative assay results were
determined from the sample S/B ratios. These are displayed in Table 2
alongside the PRRS IDEXX X3 assay results.
Using these results the sensitivity, specificity and PPV and NPV
results for the PRRSV MIA were calculated according to Yerushalmy
[18,19] see Table 3 below.
The mean PRRSV Magneto-immunoassay S/B ratio of all IDEXX
confirmed positive and negative porcine sera tested is shown in Fig. 10.
This cut-off has clearly separated two groups within the data, IDEXX
confirmed positives mean S/B ratio −1.164 +/−0.08 and IDEXX X3
confirmed negatives S/B ratio −0.830 +/−0.04. The lower S/B ratio
Fig. 9. Effect of particle number on competition in the PRRSV magneto- im-
munoassay by PRRSV antibody positive and negative control serum.
Table 1
PRRSV MIA results for a range of dilutions of LSI-EU PRRSV positive control
serum and determination of the PRRSV MIA cut-off value.
Sample (S) Mean change in
voltage (mV)
n = 3
Standard
error
PRRSV MIA
S/B ratio
PRRS IDEXX
X3 positive
LSI 1 in 200 5.03 0.783 1.378 P
LSI 1 in 400 4.53 0.207 1.241 P
LSI 1 in 800 4.10 0.367 1.123 P
LSI 1 in 2000 3.60 0.205 0.986 N
Blank (B) 3.65 0.152 1.000 NR
Key – Blank – PRRSV Orf 7 (5 μg/ml).
MIA Cut-off value – 1.123 ± 0.986/2 = 1.06.
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range for confirmed positives was 1.084 which is comparable with the
cut-off determined using the PRRSV LSI-EU control positive at 1/800
and 1/2000 dilutions. Comparing the data from the PRRSV Magneto-
immunoassay with the PRRS IDEXX X3 Gold standard, shows good
agreement between the two assays. The PRRSV Magneto-immunoassay
demonstrated a sensitivity of 73% and a PPV of 79% and specificity of
100% with a negative predictive value of 100%.
5. Discussion
Rapid diagnosis of Porcine Reproductive and Respiratory Virus
(PRRSV) infection is essential to enable timely action to prevent spread
of the infection. Current surveillance involves taking blood samples
which are then sent to a central laboratory for serology, i.e. the de-
tection of specific anti-PRRSV antibodies by ELISA. Several ELISA based
assays are available commercially for PRRSV serology and have been
compared for differences in specificity and diagnostic sensitivity [20].
The results showed significant differences in specificity and diagnostic
sensitivity between the compared kits. These differences in the per-
formance were particularly significant on PRRSV-negative farms, or
farms with PRRSV stable sow herds. Therefore some ELISAs gave results
that did not accurately detect the infection status in specific age groups.
In addition ELISA assays require specialist equipment and personnel to
perform the assays. Samples can deteriorate during transportation to a
central laboratory and results are only reported after several days.
Magneto-immunoassays have been developed in other im-
munoassay formats and sample types, the assays are very rapid giving
results in minutes and are less prone to interference from matrix effects
than other types of immunoassays. In this study we developed a com-
petitive magneto-immunoassay, for the detection of specific PRRSV
antibodies using commercially available PRRSV control sera LSI and
MRI. PMP number, antibody loading and PMP blocking agent all in-
fluenced the sensitivity of the magneto-immunoassay, but the largest
impact on sensitivity was the length of time the external magnet was
applied before magnetometer readings were taken. Very short magnet
application enabled the competition between specific and high affinity
anti-PRRSV antibody present in the serum and anti-PRRSV antibody
present on the PMPs for PRRSV Orf7 (PRRSV capsid protein) present on
the sensor surface to be observed. Longer application of the external
magnet under the sensor resulted in non-specific interference of low
affinity antibody present in the serum. Comparison of the data obtained
with the same samples in the PRRSV Magneto-immunoassay and PRRS
IDEXX X3 ELISA showed good agreement between the two assays.
Improvement of the sensitivity of the Magneto-immunoassay by minor
adjustment of PMP number and the magnetic dwell time are possible.
Further work with a larger sample size of field samples will be neces-
sary to validate the PRRSV magneto-immunoassay and cut-off de-
termination with fresh serum samples.
6. Conclusions
This study is the first published magneto-immunoassay developed
for the serological diagnosis of infection with this device. The magneto-
immunoassay gives results in minutes, the assay and magnetometer are
portable and are relatively inexpensive and can be operated by un-
skilled personnel.
Existing ELISA based serological diagnostics are often confounded
by analytical interference e.g. non-specific interactions by heterophilic
antibodies present in serum giving a high false positive rates [21]. The
second version of the IDEXX PRRSV assay, the IDEXX PRRSV X2 assay
using full length PRRSV Orf7 as antigen detected a relatively high rate
of false positives [22]. In IDEXX PRRSV X3 the full length sequence of
PRRSV Orf7 was replaced with peptide fragments of PRRSV Orf7,
eliminating regions of the protein that were highly susceptible to in-
teracting with substances causing analytical interference. In the mag-
neto-immunoassay described we have used the full length sequence of
PRRSV Orf7 and have found that this assay is less susceptible to in-
terference. We suggest that this occurs due to reduction in incubation
time from hours to minutes, leading to high affinity specific anti-PRRSV
antibodies interacting with the antigen.
We have shown in a pilot study that the magneto-immunoassay
results for IDEXX X3 positive and negative field serum samples were in
good agreement with results from the gold standard assay. False ne-
gatives could be eliminated in the future by using fresh serum samples
Table 2
Comparison of PRRSV Magneto-immunoassay S/B ratios with IDEXX X3 S/P
ratios.
Serum
sample
PRRSV MIA
S/B
Result cut-off
1.06
PRRS X3
IDEXX S/P
Result cut-off
<0.4
1 1.256 P 1.35 P
2 0.874 N <0.4 N
3 1.297 P 1.46 P
4 1.166 P 2.06 P
5 0.894 N 1.75 P
6 0.842 N <0.4 N
7 1.368 P 1.18 P
8 1.000 N <0.4 N
9 1.605 P 2.11 P
10 0.789 N <0.4 N
11 1.105 P 2.08 P
12 1.052 N <0.4 N
13 1.184 P 1.83 P
14 0.710 N <0.4 N
15 0.984 N <0.4 N
16 1.343 P 1.2 P
17 0.702 N <0.4 N
18 0.783 N <0.4 N
19 0.783 N 1.47 P
20 0.797 N 1.02 P
21 0.594 N <0.4 N
22 0.790 N <0.4 N
Results True positive
– 8
True negative
– 11
False positive
– 0
False negative –
3
Table 3
Summary results of the PRRSV Magneto-immunoassay in comparison to the
PRRS IDEXX X3 ELISA.
Samples Sensitivity Specificity PPV NPV
Porcine serum N = 22 73% 100% 100% 79%
Fig. 10. Comparison of IDEXX X3 S/P ratio results with MIA S/B ratio results
for IDEXX X3 confirmed PRRSV antibody positive and negative serum samples.
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rather than freeze thawed and further modifications of the antibody
concentration, PMP concentration and magnetic “dwell time”. Larger
numbers of field samples from a range of farming situations tested in
parallel with the PRRSV IDEXX X3 assay will be performed as part of
future work to validate the PRRSV magneto-immunoassay. In addition
the performance of the PRRSV magneto-immunoassay will be evaluated
with porcine saliva samples as these have been shown to be an alter-
native sample to use with PRRSV ELISA's [23]. The advantage of using
saliva is non-invasive and therefore a veterinary surgeon is not essential
to obtain the sample. The anti-PRRSV antibody magneto-immunoassay
shows promise for ‘on farm’ rapid, cost effective and accurate diagnosis
of PRRSV infection in farmed pigs. Use of this assay would prevent
sample deterioration due to delay between sample collection and assay
at a central lab. The immediate availability of results would enable
rapid action to be taken by veterinary surgeons to control the spread of
PRSSV infection. This technology could be applied to other PRRSV
antigens e.g. non-structural protein 7 (Nsp7), [24] and in the ser-
ological detection of other infections in a wide range of species. The
RCM has the potential to be developed as a multi-analyte testing plat-
form.
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